Unknown

Dataset Information

Chlorpromazine affects glioblastoma bioenergetics by interfering with pyruvate kinase M2.


ABSTRACT: Glioblastoma (GBM) is the most frequent and lethal brain tumor, whose therapeutic outcome - only partially effective with current schemes - places this disease among the unmet medical needs, and effective therapeutic approaches are urgently required. In our attempts to identify repositionable drugs in glioblastoma therapy, we identified the neuroleptic drug chlorpromazine (CPZ) as a very promising compound. Here we aimed to further unveil the mode of action of this drug. We performed a supervised recognition of the signal transduction pathways potentially influenced by CPZ via Reverse-Phase Protein microArrays (RPPA) and carried out an Activity-Based Protein Profiling (ABPP) followed by Mass Spectrometry (MS) analysis to possibly identify cellular factors targeted by the drug. Indeed, the

SUBMITTER: Abbruzzese C 

PROVIDER: S-EPMC10719363 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature